1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Continuing Resolution Passage Means FDA Funds Stuck At 2019 Levels Through November

 
• By Sue Darcey

The US Senate and House have both approved continuing resolution bills that President Trump is expected to sign shortly to keep the federal government running through 21 November – but that means that the FDA will be stuck at its 2019 funding level until then.

Government spending just ahead . Street exit sign showing the increase of government spending in the future. - Illustration

Passage of a continuing resolution by the US Congress on 26 September will keep federal agencies including the US Food and Drug Administration open through the middle of November, but that means the agency's device center will have less money for device approvals over the next two months. President Trump is expected to sign the CR bill this weekend.

The continuing resolution keeps the Center for Devices and Radiological Health (CDRH) at its annual 2019 spending level of $387m in budget appropriations (plus 2019-level medical device user fees), and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 
• By Amanda Maxwell

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 
• By Brian Bossetta

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.

UK Take Care! Regulatory And Market Access Reforms Must Not Shut Out Medtech Growth

 
• By Ashley Yeo

Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.